Dr Skoulidis obtained a Medical Degree from the Aristotle University of Thessaloniki, Greece in 2000 and a PhD from the University of Cambridge, UK in 2011. He completed general medicine residency and medical oncology fellowship training in Cambridge and London, UK before moving to the University of Texas MD Anderson Cancer Center in 2013, where he is currently a Tenured Associate Professor (Physician Scientist) in the Department of Thoracic/Head and Neck Medical Oncology.

Dr Skoulidis’ laboratory is focused on (a) unraveling the molecular and clinical heterogeneity of KRAS-mutant non-small cell lung cancer (NSCLC) and developing novel therapeutic strategies to target KRAS-mutant lung tumors; (b) maximizing the therapeutic potential of mutant-selective direct KRAS inhibitors and (c) elucidating the impact of individual somatic genomic alterations on the NSCLC immune contexture and immunotherapy response, with the goal of developing novel precision oncogenotype-tailored immunotherapeutic strategies. Dr Skoulidis has received a number of awards for his research including a 2019 AACR NextGen Star award. His work has been published in high-impact scientific journals including The New England Journal of Medicine, Cancer Discovery, Cancer Cell, Nature Reviews Cancer and his research has attracted research funding from the NIH/NCI, the Cancer Prevention and Research Institute of Texas and the US Department of Defense.